Malarikova, D.; Berkova, A.; Obr, A.; Blahovcova, P.; Svaton, M.; Forsterova, K.; Kriegova, E.; Prihodova, E.; Pavlistova, L.; Petrackova, A.;
et al. Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. Cancers 2020, 12, 2120.
https://doi.org/10.3390/cancers12082120
AMA Style
Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K, Kriegova E, Prihodova E, Pavlistova L, Petrackova A,
et al. Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. Cancers. 2020; 12(8):2120.
https://doi.org/10.3390/cancers12082120
Chicago/Turabian Style
Malarikova, Diana, Adela Berkova, Ales Obr, Petra Blahovcova, Michael Svaton, Kristina Forsterova, Eva Kriegova, Eva Prihodova, Lenka Pavlistova, Anna Petrackova,
and et al. 2020. "Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy" Cancers 12, no. 8: 2120.
https://doi.org/10.3390/cancers12082120
APA Style
Malarikova, D., Berkova, A., Obr, A., Blahovcova, P., Svaton, M., Forsterova, K., Kriegova, E., Prihodova, E., Pavlistova, L., Petrackova, A., Zemanova, Z., Trneny, M., & Klener, P.
(2020). Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. Cancers, 12(8), 2120.
https://doi.org/10.3390/cancers12082120
